Last Updated: June 9, 2026

Details for Patent: 5,501,236


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,501,236
Title:Nicotine-impermeable container and method of fabricating the same
Abstract:The present invention relates to a nicotine-impermeable container and a method for fabricating same. Additionally, the invention relates to a nicotine inhaling device which allows a user to ingest nicotine vapors orally. The nicotine inhaling device of the present invention is primarily directed to a device which can be used as a smoking cessation aid.
Inventor(s):Ira Hill, Bengt E. Malmborg, Ronald G. Oldham, James E. Turner, Michael P. Ellis, Sven-Bo/ rje Andersson
Assignee: McNeil AB
Application Number:US08/400,595
Patent Claim Types:
see list of patent claims
Use; Formulation; Compound; Delivery;
Patent landscape, scope, and claims:

United States Patent 5,501,236: Nicotine Delivery System With Shelf-Life-Extending Barrier

US Drug Patent 5,501,236 claims a nicotine delivery system designed to maintain nicotine integrity for extended shelf life by enclosing a measured nicotine reservoir within a self-sealed, nicotine-impermeable, heat-sealed barrier made from a copolymer of acrylonitrile and methyl acrylate, optionally reinforced with metal foil and maintained in an oxygen-free environment using inert gas (nitrogen). The core IP value is the combination of (i) barrier polymer chemistry and (ii) packaging architecture that blocks nicotine migration and oxygen ingress.


What does claim 1 actually require (scope lock-in)?

Claim 1 elements (minimum infringement checklist)

Claim 1 depends on all three structural/functional requirements below:

  1. Nicotine reservoir (measured amount)

    • “A nicotine reservoir for holding and dispersing a measured amount of nicotine.”
  2. Self-sealed, nicotine-impermeable barrier

    • Barrier encloses the nicotine reservoir.
    • Barrier is nicotine impermeable.
    • Barrier includes at least one nicotine barrier layer formed essentially of a copolymer of acrylonitrile and methyl acrylate.
  3. Heat-sealed adjacent surfaces forming a continuous nicotine barrier

    • “The barrier layer including at least two adjacent surfaces heat sealed to form a continuous nicotine impermeable barrier so that the nicotine can be prevented from migration outside the barrier.”

Scope implications

  • Polymer identity is mandatory. The barrier layer is “formed essentially of” a specific copolymer family: acrylonitrile + methyl acrylate. A barrier that uses a different polymer class (even if it is nicotine-impermeable) does not cleanly meet the literal language of claim 1.
  • Architecture is mandatory. The claim requires heat sealing of adjacent surfaces to form a continuous impermeable barrier. A package that uses adhesives, mechanical seals, or solvent-weld methods without the claim’s “heat sealed” characteristic is at risk of not meeting claim 1 literally.
  • Functional outcome is embedded. The heat-sealed configuration must prevent “migration outside the barrier,” tying claim scope to an impermeability and seal integrity concept.

How do dependent claims narrow the protected space?

Claim 2: Oxygen-free environment inside the barrier

  • “The barrier encloses the reservoir in an essentially oxygen-free environment.”

Scope effect: Adds internal atmosphere constraints. A system with ambient oxygen inside the barrier does not map.

Claim 3: Oxygen-free maintained by inert gas

  • “Said essentially oxygen-free environment is maintained by a gas inert to nicotine.”

Scope effect: Requires an inert gas generation/containment approach, not just a pre-evacuation and backfill at packaging. The language “maintained by” focuses on the in-use atmosphere over shelf life.

Claim 4: Inert gas is nitrogen

  • “Nitrogen.”

Scope effect: Further limits the inert gas to nitrogen specifically (if litigated as written).

Claim 5: Metal foil reinforcement

  • “Barrier further includes a second barrier layer formed of metal foil adhered to at least a portion of the outer surface of the nicotine barrier layer.”

Scope effect: Adds a layered barrier structure: polymer barrier + adhered metal foil on the outer surface of that polymer barrier layer.

Claim 6: Foil is aluminum

  • “Aluminum foil.”

Scope effect: Narrows metal foil to aluminum.

Claim 7: Reservoir formulation architecture

  • “Reservoir comprises a porous polymer plug charged with a solution including at least nicotine free-base.”

Scope effect: Adds reservoir construction: porous plug and solution containing at least nicotine free-base (not solely nicotine salt).


What is the practical “claim map” for infringement risk?

Literal claim 1 requires all of the following:

  • A nicotine delivery system with a measured nicotine reservoir.
  • A self-sealed, nicotine-impermeable barrier.
  • Barrier contains a layer “essentially of” acrylonitrile/methyl acrylate copolymer.
  • Adjacent barrier surfaces heat sealed to form a “continuous” impermeable barrier.

Common design variations and whether they align

  • Different barrier chemistry (e.g., ethylene-vinyl alcohol copolymer, PVDC, multilayer PET/nylon): likely fails “formed essentially of” copolymer language.
  • Non-heat sealing closure (e.g., ultrasonic welding, adhesive lamination only): likely fails the “heat sealed” limitation.
  • Non-migration-control barrier (barrier that reduces permeability but still allows measurable nicotine migration): fails the “so that nicotine can be prevented from migration” functional requirement.

What does the “essentially of” language do to polymer scope?

The claim uses “formed essentially of” rather than a strict “consists of.” That typically allows minor components or processing aids that do not change the barrier’s essential copolymer identity. For enforcement planning, the critical question becomes whether an accused barrier layer contains the acrylonitrile + methyl acrylate copolymer as the dominant barrier-forming component and whether other components materially replace it.

Business takeaway: the claim targets a specific barrier copolymer family, but leaves room for blend/processing flexibility.


How the oxygen-free dependent claims affect packaging strategy

  • Claims 2-4 convert the barrier from a purely nicotine-impermeable structure into a nicotine- and oxygen-protective system.
  • Shelf-life degradation in nicotine products is frequently oxygen-driven (oxidation). Claims 2-4 make that protective function part of infringement scope.

Nitrogen limitation in claim 4

A system that uses argon, helium, or another inert gas may avoid claim 4 while still potentially meeting claim 3 if it qualifies as “gas inert to nicotine.” Claim 4 narrows only if the nitrogen requirement is treated as literal and not substituted by equivalents.


How claim 5-6 layered barriers change the technology and freedom-to-operate picture

Claim 5 adds metal foil adhered to the outer surface of the polymer barrier layer. This shifts infringement from “polymer-only packaging” into “polymer + foil laminates.”

  • Many packaging approaches use foil or metallized film, but claim 5 is specific about metal foil and adhesion to the outer surface of the nicotine barrier layer.
  • Claim 6 then narrows foil to aluminum.

For FTO, the higher-risk zone is products using:

  • An acrylonitrile/methyl acrylate copolymer barrier (or substantially the same),
  • Combined with heat sealing of adjacent surfaces, and
  • A polymer-foil laminated barrier on the exterior.

How claim 7 changes formulation and product architecture scope

Claim 7 restricts reservoir to a porous polymer plug charged with a solution containing nicotine free-base.

Scope effects

  • A reservoir holding nicotine salts without free-base might not meet the “including at least nicotine free-base” requirement.
  • A reservoir built on microcapsules, membranes, or gel matrices without a porous polymer plug structure is less likely to fit.

Claim 7 narrows to a specific internal nicotine carrier architecture.


What is the likely “center of gravity” of the patent?

Across the claim set, the center of gravity sits in claim 1:

  • Barrier polymer: acrylonitrile/methyl acrylate copolymer
  • Seal method: heat sealing adjacent surfaces
  • Barrier function: nicotine impermeability preventing migration

Dependent claims layer on:

  • Oxygen exclusion via inert gas (nitrogen)
  • Outer aluminum foil reinforcement
  • Porous polymer plug reservoir with nicotine free-base

This means the strongest enforcement and licensing position is likely on the barrier design and seal method, with dependent claims expanding value when products adopt those added shelf-life protections.


Patent landscape analysis: where this claim set sits in the competitive space

Because only the claim text is provided, this analysis focuses on scope-positioning rather than a citation-based mapping of other patents. The landscape can still be meaningfully framed in terms of how competitors typically protect the shelf life of nicotine:

1) Competitors protecting shelf life by barrier chemistry

Common alternatives include oxygen barrier polymers and nicotine-migration control materials that are not acrylonitrile/methyl acrylate copolymers. Under the provided claim language, those alternatives:

  • may not meet claim 1 literal polymer identity;
  • may still create partial overlap for oxygen barriers if they also rely on inert-gas environments (claims 2-4) but would likely avoid claim 1 on polymer selection.

2) Competitors protecting shelf life by packaging process and sealing

Heat sealing is explicitly required in claim 1. Competitors using other closure technologies:

  • can reduce migration without “heat sealing adjacent surfaces”;
  • may avoid claim 1 while still using nicotine-impermeable layers.

3) Competitors using metal foil or metallized layers

Many commercial barriers incorporate foil for oxygen control or mechanical strength. Under the provided claims:

  • aluminum foil laminated to the outer surface of the polymer barrier layer is a direct match for claims 5-6 if the polymer core also matches.

4) Competitors using oxygen-free headspace

Inert gas blanketing is common in packaging. Under claims 2-4:

  • any approach that does not achieve “essentially oxygen-free environment” and does not “maintain” it via inert gas fails claim 2-3;
  • nitrogen specifically is required for claim 4.

5) Competitors using different nicotine reservoir architectures

Porous polymer plugs loaded with nicotine free-base are a narrower internal architecture. Many products use salt forms, gels, or capillary matrices. Claim 7 therefore carves out a specific reservoir construction approach.


Scope summary by claim layer (what a design must have to be caught)

Claim Added limitation “Caught if” checklist
1 Nicotine-impermeable barrier layer “essentially of” acrylonitrile/methyl acrylate copolymer; adjacent surfaces heat sealed into continuous barrier Polymer identity + heat-sealed continuous seal + nicotine migration prevention
2 Essentially oxygen-free environment enclosed Oxygen exclusion inside barrier
3 Oxygen-free maintained by inert gas Inert gas used as ongoing maintenance of low oxygen
4 Inert gas is nitrogen Nitrogen specifically
5 Second barrier layer is metal foil adhered to outer surface Polymer barrier + adhered metal foil exterior
6 Foil is aluminum Aluminum foil exterior
7 Reservoir includes porous polymer plug charged with solution with nicotine free-base Porous plug + nicotine free-base in the charged solution

Key Takeaways

  • Claim 1 is the enforceable core: nicotine reservoir + self-sealed nicotine-impermeable barrier with a layer “essentially of” acrylonitrile/methyl acrylate copolymer, with heat-sealed adjacent surfaces forming a continuous barrier that prevents nicotine migration.
  • Claims 2-4 add headspace oxygen protection: essentially oxygen-free environment maintained by inert gas, specifically nitrogen for claim 4.
  • Claims 5-6 add a laminated exterior barrier: aluminum foil adhered to the outer surface of the polymer barrier layer.
  • Claim 7 narrows the internal nicotine carrier: reservoir must use a porous polymer plug charged with a solution including nicotine free-base.
  • Product designs that miss any single mandatory limitation face reduced literal infringement risk, especially for the polymer chemistry and heat-sealed continuous barrier requirements in claim 1.

FAQs

  1. Is the acrylonitrile/methyl acrylate copolymer required in every claim?
    Yes for claim 1 and all dependent claims that depend on claim 1.

  2. Does using any inert gas satisfy claim 4?
    No. Claim 4 requires nitrogen.

  3. Does claim 5 require foil on the inside or outside of the polymer barrier?
    Outside. It requires metal foil adhered to at least a portion of the outer surface of the nicotine barrier layer.

  4. Can a reservoir use nicotine salt forms and still meet claim 7?
    Claim 7 requires a solution including at least nicotine free-base, so pure nicotine salt formulations are outside the literal scope.

  5. Does the patent cover oxygen-free packaging without heat sealing?
    Heat sealing is a limitation in claim 1 and therefore must be present for infringement of the full claimed structure.


References

[1] United States Patent 5,501,236, “Nicotine delivery system with an extended shelf life” (claims provided in prompt).

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 5,501,236

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.